Skip to main content

Abbvie Value Stock - Dividend - Research Selection


ISIN: US00287Y1091 , WKN: A1J84E

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines, including more than 50 investigational programs in clinical development across such important medical specialties as immunology, virology, oncology and neurology, with additional targeted investment in cystic fibrosis and women's health. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. On June 1, 2016, AbbVie acquired all of the outstanding equity interests in Stemcentrx, Inc. (Stemcentrx), a privately held biotechnology company. The aggregate upfront consideration paid by AbbVie in connection with the acquisition was approximately $5.8 billion. The transaction expands AbbVie’s oncology pipeline by adding the late-stage asset rovalpituzumab tesirine (Rova-T), four additional early-stage clinical compounds in solid tumor indications and a significant portfolio of pre-clinical assets. Rova-T is currently in registrational trials for small cell lung cancer and in early-stage clinical development for other solid tumors. Segments AbbVie operates in one business segment—pharmaceutical products. See Note 15 to the Consolidated Financial Statements and the sales information related to HUMIRA included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations."
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


MGV: A Cost-Efficient Vanguard Value ETF For Diversification

Vanguard Mega Cap Value ETF is a cost-efficient way for investors to gain exposure to largest value stocks in the market. See why I'm bullish on MGV fund.

2 Top Dividend Kings to Buy for the Long Haul

Dividend Kings are among the best stocks that income-seeking investors can turn to in these uncertain days. Let's consider a duo of corporations in this category that investors should consider buying and holding on to for a while: Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV). Abbott Laboratories is known as a leader in the medical devices field although it has a presence in several other areas, including nutrition and a generic pharmaceutical unit that targets primarily developing countries.

15 Large-Cap Stocks Hedge Funds Are Dumping

In this article, we will look at the 15 large-cap stocks hedge funds are dumping. If you want to explore similar stocks, you can also take a look at 5 Large-Cap Stocks Hedge Funds Are Dumping. We are now approaching the end of the first quarter of 2023 and the markets are exhibiting an upward […]

2 High-Yield Dividend Stocks to Buy in March

Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.

ILCV: There Are Better Options Among Large Cap Value ETFs

iShares Morningstar Large-Cap Value ETF implements a strategy similar to the S&P 500 Value Index. Click here to see whether ILCV is a Buy.

How To Allocate $25,000 Among 10 Dividend Income And Dividend Growth Companies And ETFs

In this article, I will show you how you could allocate $25,000 among 10 dividend income and dividend growth companies as well as ETFs. Read more here.

AbbVie Inc. stock rises Friday, still underperforms market

Shares of AbbVie Inc. rallied 1.09% to $156.06 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

Q4 2022 AdTheorent Holding Company Inc Earnings Call

Q4 2022 AdTheorent Holding Company Inc Earnings Call

Could This Humira Biosimilar Be a Winner for Amgen?

At the end of January, Amgen (NASDAQ: AMGN) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (NYSE: ABBV) star immunology drug called Humira. Amgen's Amjevita received approval from the U.S. Food and Drug Administration (FDA) as a biosimilar in 2016.

Viatris joins AbbVie and Lilly in protesting against U.K. drug pricing deal

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.